Myocardial Infarction Clinical Trial
— P-HEARTNEROfficial title:
Impact on the Physical Activity Level of Coronary Patients in Phase 3 of a Therapeutic Educational Consolidation Program Involving a "Patient Partner" Associated With a Healthcare Professional. A Randomized Controlled Trial.
Following myocardial infarction, cardiac rehabilitation has undeniable benefits on criteria such as cardiovascular mortality and coronary recurrence. Cardiac rehabilitation consists of 3 phases: 1. immediate post-acute, in a cardiology department, 2. active cardiac rehabilitation for several weeks under medical supervision as an inpatient or outpatient, 3. Resumption of active life by the patient. Indeed, one of the major aims of secondary prevention is long-term adherence to physical activity.However, only 20% to 40% of coronary patients remain physically active at 6 months or 1 year, and the effects of Phase 2 cardiac rehabilitation are not maintained. Managing to maintain at least a moderate level of physical activity after Phase 2 of CR is a major objective. Various interventions (booklets, applications, activity programs, motivational talks led by healthcare professionals have been tested and compared with the usual care in Phase 3 cardiac rehabilitation. An effect seems to exist on the level of physical activity reported, but with a significant evaluation bias. This study aims to use accelerometry to evaluate the 6-month efficacy of the therapeutic education program for consolidation in phase 3 of Cardiovascular Rehabilitation involving a patient partner and a caregiver on moderate-to-sustained physical activity (> 3 METs) in coronary patients on Phase 3 of cardiac rehabilitation compared with usual rehabilitation management.
Status | Recruiting |
Enrollment | 84 |
Est. completion date | March 31, 2026 |
Est. primary completion date | October 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient of legal age (= 18 years). - Patient having undergone phase 2 treatment in the cardiovascular rehabilitation department of the CHU for myocardial infarction. - Patient with a means of communication that allows easy internet connection (i.e. a smartphone). - Patient fluent in French. - Patient who has given free informed consent. - Patient affiliated or beneficiary of a health insurance scheme. Exclusion Criteria: - Patient with severe or unstable comorbidity (respiratory insufficiency renal failure, decompensated heart failure). heart failure). - Patient with unstable angina. - Patient with contraindications to physical activity following physical activity following cardiovascular rehabilitation (according to medical discussion, based on the recommendations of the French Society of Cardiology). - Patient with no suitable means of communication. - Patient under court protection, guardianship or curatorship. - Pregnant, parturient or breast-feeding patients. |
Country | Name | City | State |
---|---|---|---|
France | CHU de Nîmes | Nimes |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Moderate-to-sustained physical activity in the Experimental Group | The accelerometer will be used to evaluate the 6-month efficacy of the therapeutic educational program for consolidation in Phase 3 of Cardiovascular Rehabilitation involving a patient partner and a caregiver and its affect on the level of moderate-to-sustained physical activity (> 3 METs) in coronary patients in Phase 3 of cardiac rehabilitation compared with usual rehabilitation management.
The amount of moderate-to-sustained physical activity (> 3 METs) will be measured in minutes per week. |
Month 6 | |
Primary | Moderate-to-sustained physical activity in Controls | The accelerometer will be used to evaluate the 6-month efficacy of the therapeutic educational program for consolidation in Phase 3 of Cardiovascular Rehabilitation involving a patient partner and a caregiver and its affect on the level of moderate-to-sustained physical activity (> 3 METs) in coronary patients in Phase 3 of cardiac rehabilitation compared with usual rehabilitation management.
The amount of moderate-to-sustained physical activity (> 3 METs) will be measured in minutes per week. |
Month 6 | |
Secondary | Moderate-to-sustained physical activity in the Experimental Group | The amount of moderate-to-sustained physical activity (> 3 METs) will be measured with the accelerometer in minutes per week. | Month 3 | |
Secondary | Moderate-to-sustained physical activity in Controls | The amount of moderate-to-sustained physical activity (> 3 METs) will be measured with the accelerometer in minutes per week. | Month 3 | |
Secondary | Number of steps taken per week in the Experimental Group | Number of steps taken per week recorded by the accelerometer | Month 0 | |
Secondary | Number of steps taken per week in the Experimental Group | Number of steps taken per week recorded by the accelerometer | Month 3 | |
Secondary | Number of steps taken per week in the Experimental Group | Number of steps taken per week recorded by the accelerometer | Month 6 | |
Secondary | Number of steps taken per week in Controls | Number of steps taken per week recorded by the accelerometer | Month 0 | |
Secondary | Number of steps taken per week in Controls | Number of steps taken per week recorded by the accelerometer | Month 3 | |
Secondary | Number of steps taken per week in Controls | Number of steps taken per week recorded by the accelerometer | Month 6 | |
Secondary | Time spent sitting/lying down per week in the Experimental Group | Time spent sitting/lying down per week recorded by the accelerometer | Month 0 | |
Secondary | Time spent sitting/lying down per week in the Experimental Group | Time spent sitting/lying down per week recorded by the accelerometer | Month 3 | |
Secondary | Time spent sitting/lying down per week in the Experimental Group | Time spent sitting/lying down per week recorded by the accelerometer | Month 6 | |
Secondary | Time spent sitting/lying down per week in Controls | Time spent sitting/lying down per week recorded by the accelerometer | Month 0 | |
Secondary | Time spent sitting/lying down per week in Controls | Time spent sitting/lying down per week recorded by the accelerometer | Month 3 | |
Secondary | Time spent sitting/lying down per week in Controls | Time spent sitting/lying down per week recorded by the accelerometer | Month 6 | |
Secondary | International Physical Activity Questionnaire Score in the Experimental Group | The short form of the International Physical Activity Questionnaire measures physical activity over the previous week and assesses the types of intensity of physical activity, and sitting time to estimate total physical activity in MET-min/week and time spent sitting. For each category of activity a maximum of 21 hours of activity are permitted a week (3 hours X 7 days).To calculate MET-minutes a week the MET value given (walking = 3.3, moderate activity = 4, vigorous activity = 8) is multiplied by the number of minutes the activity was carried out, and again by the number of days that that activity was undertaken. For example if someone reports walking for 30 minutes 5 days a week then the total MET-minutes for that activity are 3.3 X 30 X 5=495 MET-minutes a week. The MET minutes achieved in each category (walking, moderate activity and vigorous activity) are then added together to get the total MET-minutes of physical activity per week. | Month 0 | |
Secondary | International Physical Activity Questionnaire Score in the Experimental Group | The short form of the International Physical Activity Questionnaire measures physical activity over the previous week and assesses the types of intensity of physical activity, and sitting time to estimate total physical activity in MET-min/week and time spent sitting. For each category of activity a maximum of 21 hours of activity are permitted a week (3 hours X 7 days).To calculate MET-minutes a week the MET value given (walking = 3.3, moderate activity = 4, vigorous activity = 8) is multiplied by the number of minutes the activity was carried out, and again by the number of days that that activity was undertaken. For example if someone reports walking for 30 minutes 5 days a week then the total MET-minutes for that activity are 3.3 X 30 X 5=495 MET-minutes a week. The MET minutes achieved in each category (walking, moderate activity and vigorous activity) are then added together to get the total MET-minutes of physical activity per week. | Month 3 | |
Secondary | International Physical Activity Questionnaire Score in the Experimental Group | The short form of the International Physical Activity Questionnaire measures physical activity over the previous week and assesses the types of intensity of physical activity, and sitting time to estimate total physical activity in MET-min/week and time spent sitting. For each category of activity a maximum of 21 hours of activity are permitted a week (3 hours X 7 days).To calculate MET-minutes a week the MET value given (walking = 3.3, moderate activity = 4, vigorous activity = 8) is multiplied by the number of minutes the activity was carried out, and again by the number of days that that activity was undertaken. For example if someone reports walking for 30 minutes 5 days a week then the total MET-minutes for that activity are 3.3 X 30 X 5=495 MET-minutes a week. The MET minutes achieved in each category (walking, moderate activity and vigorous activity) are then added together to get the total MET-minutes of physical activity per week. | Month 6 | |
Secondary | International Physical Activity Questionnaire Score in Controls | The short form of the International Physical Activity Questionnaire measures physical activity over the previous week and assesses the types of intensity of physical activity, and sitting time to estimate total physical activity in MET-min/week and time spent sitting. For each category of activity a maximum of 21 hours of activity are permitted a week (3 hours X 7 days).To calculate MET-minutes a week the MET value given (walking = 3.3, moderate activity = 4, vigorous activity = 8) is multiplied by the number of minutes the activity was carried out, and again by the number of days that that activity was undertaken. For example if someone reports walking for 30 minutes 5 days a week then the total MET-minutes for that activity are 3.3 X 30 X 5=495 MET-minutes a week. The MET minutes achieved in each category (walking, moderate activity and vigorous activity) are then added together to get the total MET-minutes of physical activity per week. | Month 0 | |
Secondary | International Physical Activity Questionnaire Score in Controls | The short form of the International Physical Activity Questionnaire measures physical activity over the previous week and assesses the types of intensity of physical activity, and sitting time to estimate total physical activity in MET-min/week and time spent sitting. For each category of activity a maximum of 21 hours of activity are permitted a week (3 hours X 7 days).To calculate MET-minutes a week the MET value given (walking = 3.3, moderate activity = 4, vigorous activity = 8) is multiplied by the number of minutes the activity was carried out, and again by the number of days that that activity was undertaken. For example if someone reports walking for 30 minutes 5 days a week then the total MET-minutes for that activity are 3.3 X 30 X 5=495 MET-minutes a week. The MET minutes achieved in each category (walking, moderate activity and vigorous activity) are then added together to get the total MET-minutes of physical activity per week. | Month 3 | |
Secondary | International Physical Activity Questionnaire Score in Controls | The short form of the International Physical Activity Questionnaire measures physical activity over the previous week and assesses the types of intensity of physical activity, and sitting time to estimate total physical activity in MET-min/week and time spent sitting. For each category of activity a maximum of 21 hours of activity are permitted a week (3 hours X 7 days).To calculate MET-minutes a week the MET value given (walking = 3.3, moderate activity = 4, vigorous activity = 8) is multiplied by the number of minutes the activity was carried out, and again by the number of days that that activity was undertaken. For example if someone reports walking for 30 minutes 5 days a week then the total MET-minutes for that activity are 3.3 X 30 X 5=495 MET-minutes a week. The MET minutes achieved in each category (walking, moderate activity and vigorous activity) are then added together to get the total MET-minutes of physical activity per week. | Month 6 | |
Secondary | Blood pressure in the Experimental Group | mm Hg | Month 0 | |
Secondary | Blood pressure in the Experimental Group | mm Hg | Month 3 | |
Secondary | Blood pressure in the Experimental Group | mm Hg | Month 6 | |
Secondary | Blood pressure in Controls | mm Hg | Month 0 | |
Secondary | Blood pressure in Controls | mm Hg | Month 3 | |
Secondary | Blood pressure in Controls | mm Hg | Month 6 | |
Secondary | Modified Borg score in the Experimental Group | The modified Borg dyspnea score uses a scale from 0 to 10 in which 0 represents no dyspnea and 10 represents maximal dyspnea. Scores are obtained at the end of the 6-minute walking test and reflect the maximum degree of dyspnea at any time during the walk test. | Month 0 | |
Secondary | Modified Borg score in the Experimental Group | The modified Borg dyspnea score uses a scale from 0 to 10 in which 0 represents no dyspnea and 10 represents maximal dyspnea. Scores are obtained at the end of the 6-minute walking test and reflect the maximum degree of dyspnea at any time during the walk test. | Month 3 | |
Secondary | Modified Borg score in the Experimental Group | The modified Borg dyspnea score uses a scale from 0 to 10 in which 0 represents no dyspnea and 10 represents maximal dyspnea. Scores are obtained at the end of the 6-minute walking test and reflect the maximum degree of dyspnea at any time during the walk test. | Month 6 | |
Secondary | Modified Borg score in Controls | The modified Borg dyspnea score uses a scale from 0 to 10 in which 0 represents no dyspnea and 10 represents maximal dyspnea. Scores are obtained at the end of the 6-minute walking test and reflect the maximum degree of dyspnea at any time during the walk test. | Month 0 | |
Secondary | Modified Borg score in Controls | The modified Borg dyspnea score uses a scale from 0 to 10 in which 0 represents no dyspnea and 10 represents maximal dyspnea. Scores are obtained at the end of the 6-minute walking test and reflect the maximum degree of dyspnea at any time during the walk test. | Month 3 | |
Secondary | Modified Borg score in Controls | The modified Borg dyspnea score uses a scale from 0 to 10 in which 0 represents no dyspnea and 10 represents maximal dyspnea. Scores are obtained at the end of the 6-minute walking test and reflect the maximum degree of dyspnea at any time during the walk test. | Month 6 | |
Secondary | Abdominal circumference in the Experimental Group | In cm | Month 0 | |
Secondary | Abdominal circumference in the Experimental Group | In cm | Month 3 | |
Secondary | Abdominal circumference in the Experimental Group | In cm | Month 6 | |
Secondary | Abdominal circumference in Controls | In cm | Month 0 | |
Secondary | Abdominal circumference in Controls | In cm | Month 3 | |
Secondary | Abdominal circumference in Controls | In cm | Month 6 | |
Secondary | Aerobic capacity in the Experimental Group | Aerobic capacity clinically measured by the 6-minute walking test (number of metres covered). | Month 0 | |
Secondary | Aerobic capacity in the Experimental Group | Aerobic capacity clinically measured by the 6-minute walking test (number of metres covered). | Month 3 | |
Secondary | Aerobic capacity in the Experimental Group | Aerobic capacity clinically measured by the 6-minute walking test (number of metres covered). | Month 6 | |
Secondary | Aerobic capacity in Controls | Aerobic capacity clinically measured by the 6-minute walking test (number of metres covered). | Month 0 | |
Secondary | Aerobic capacity in Controls | Aerobic capacity clinically measured by the 6-minute walking test (number of metres covered). | Month 3 | |
Secondary | Aerobic capacity in Controls | Aerobic capacity clinically measured by the 6-minute walking test (number of metres covered). | Month 6 | |
Secondary | Cholesterol in the Experimental Group | mg/dL | Month 0 | |
Secondary | Cholesterol in the Experimental Group | mg/dL | Month 3 | |
Secondary | Cholesterol in the Experimental Group | mg/dL | Month 6 | |
Secondary | Cholesterol in Controls | mg/dL | Month 0 | |
Secondary | Cholesterol in Controls | mg/dL | Month 3 | |
Secondary | Cholesterol in Controls | mg/dL | Month 6 | |
Secondary | Low-density lipoprotein in the Experimental Group | mg/dL | Month 0 | |
Secondary | Low-density lipoprotein in the Experimental Group | mg/dL | Month 3 | |
Secondary | Low-density lipoprotein in the Experimental Group | mg/dL | Month 6 | |
Secondary | Low-density lipoprotein in Controls | mg/dL | Month 0 | |
Secondary | Low-density lipoprotein in Controls | mg/dL | Month 3 | |
Secondary | Low-density lipoprotein in Controls | mg/dL | Month 6 | |
Secondary | High-density lipoprotein in the Experimental Group | mg/dL | Month 0 | |
Secondary | High-density lipoprotein in the Experimental Group | mg/dL | Month 3 | |
Secondary | High-density lipoprotein in the Experimental Group | mg/dL | Month 6 | |
Secondary | High-density lipoprotein in Controls | mg/dL | Month 0 | |
Secondary | High-density lipoprotein in Controls | mg/dL | Month 3 | |
Secondary | High-density lipoprotein in Controls | mg/dL | Month 6 | |
Secondary | Triglycerides in the Experimental Group | mg/dL | Month 0 | |
Secondary | Triglycerides in the Experimental Group | mg/dL | Month 3 | |
Secondary | Triglycerides in the Experimental Group | mg/dL | Month 6 | |
Secondary | Triglycerides in Controls | mg/dL | Month 0 | |
Secondary | Triglycerides in Controls | mg/dL | Month 3 | |
Secondary | Triglycerides in Controls | mg/dL | Month 6 | |
Secondary | Blood glucose levels in the Experimental Group | mg/dL | Month 0 | |
Secondary | Blood glucose levels in the Experimental Group | mg/dL | Month 3 | |
Secondary | Blood glucose levels in the Experimental Group | mg/dL | Month 6 | |
Secondary | Blood glucose levels in Controls | mg/dL | Month 0 | |
Secondary | Blood glucose levels in Controls | mg/dL | Month 3 | |
Secondary | Blood glucose levels in Controls | mg/dL | Month 6 | |
Secondary | Compliance with medication in the Experimental Group | YES/NO | Month 0 | |
Secondary | Compliance with medication in the Experimental Group | YES/NO | Month 3 | |
Secondary | Compliance with medication in the Experimental Group | YES/NO | Month 6 | |
Secondary | Compliance with medication in Controls | YES/NO | Month 0 | |
Secondary | Compliance with medication in Controls | YES/NO | Month 3 | |
Secondary | Compliance with medication in Controls | YES/NO | Month 6 | |
Secondary | Motivation for doing physical activity in the Experimental Group | The EMAPS scale (Echelle de Motivation envers l'Activité Physique en contexte de Santé = Scale for Motivation for Physical Activity in the Context of Health).This is an 18-item questionnaire with scores from 1 to 7. Depending on the patient's answers to the questions, the type and extent of motivation are defined. Score 18 - 126 | Month 0 | |
Secondary | Motivation for doing physical activity in the Experimental Group | The EMAPS scale (Echelle de Motivation envers l'Activité Physique en contexte de Santé = Scale for Motivation for Physical Activity in the Context of Health).This is an 18-item questionnaire with scores from 1 to 7. Depending on the patient's answers to the questions, the type and extent of motivation are defined. Score 18 - 126 | Month 3 | |
Secondary | Motivation for doing physical activity in the Experimental Group | The EMAPS scale (Echelle de Motivation envers l'Activité Physique en contexte de Santé = Scale for Motivation for Physical Activity in the Context of Health).This is an 18-item questionnaire with scores from 1 to 7. Depending on the patient's answers to the questions, the type and extent of motivation are defined. Score 18 - 126 | Month 6 | |
Secondary | Motivation for doing physical activity in Controls | The EMAPS scale (Echelle de Motivation envers l'Activité Physique en contexte de Santé = Scale for Motivation for Physical Activity in the Context of Health).This is an 18-item questionnaire with scores from 1 to 7. Depending on the patient's answers to the questions, the type and extent of motivation are defined. Score 18 - 126 | Month 0 | |
Secondary | Motivation for doing physical activity in Controls | The EMAPS scale (Echelle de Motivation envers l'Activité Physique en contexte de Santé = Scale for Motivation for Physical Activity in the Context of Health).This is an 18-item questionnaire with scores from 1 to 7. Depending on the patient's answers to the questions, the type and extent of motivation are defined. Score 18 - 126 | Month 3 | |
Secondary | Motivation for doing physical activity in Controls | The EMAPS scale (Echelle de Motivation envers l'Activité Physique en contexte de Santé = Scale for Motivation for Physical Activity in the Context of Health).This is an 18-item questionnaire with scores from 1 to 7. Depending on the patient's answers to the questions, the type and extent of motivation are defined. Score 18 - 126 | Month 6 | |
Secondary | Exercise Confidence Survey in the Experimental Group | French version of the "Exercise Confidence Survey" for regular physical activity) according to Eeckhout et al. 2012. The ECS questionnaire measures perceived self-efficacy for regular physical activity. It has two dimensions in the Exercise Confidence Survey: "sticking to it" and "making time for exercise". The survey has 8 questions to be answered by "I Know I can" (1 point) "Maybe I can" (3 points) or "I Know I cannot" (5 points). (Sallis et al., 1996) | Month 0 | |
Secondary | Exercise Confidence Survey in the Experimental Group | French version of the "Exercise Confidence Survey" for regular physical activity) according to Eeckhout et al. 2012. The ECS questionnaire measures perceived self-efficacy for regular physical activity. It has two dimensions in the Exercise Confidence Survey: "sticking to it" and "making time for exercise". The survey has 8 questions to be answered by "I Know I can" (1 point) "Maybe I can" (3 points) or "I Know I cannot" (5 points). (Sallis et al., 1996) | Month 3 | |
Secondary | Exercise Confidence Survey in the Experimental Group | French version of the "Exercise Confidence Survey" for regular physical activity) according to Eeckhout et al. 2012. The ECS questionnaire measures perceived self-efficacy for regular physical activity. It has two dimensions in the Exercise Confidence Survey: "sticking to it" and "making time for exercise". The survey has 8 questions to be answered by "I Know I can" (1 point) "Maybe I can" (3 points) or "I Know I cannot" (5 points). (Sallis et al., 1996) | Month 6 | |
Secondary | Exercise Confidence Survey in Controls | French version of the "Exercise Confidence Survey" for regular physical activity) according to Eeckhout et al. 2012. The ECS questionnaire measures perceived self-efficacy for regular physical activity. It has two dimensions in the Exercise Confidence Survey: "sticking to it" and "making time for exercise". The survey has 8 questions to be answered by "I Know I can" (1 point) "Maybe I can" (3 points) or "I Know I cannot" (5 points). (Sallis et al., 1996) | Month 0 | |
Secondary | Exercise Confidence Survey in Controls | French version of the "Exercise Confidence Survey" for regular physical activity) according to Eeckhout et al. 2012. The ECS questionnaire measures perceived self-efficacy for regular physical activity. It has two dimensions in the Exercise Confidence Survey: "sticking to it" and "making time for exercise". The survey has 8 questions to be answered by "I Know I can" (1 point) "Maybe I can" (3 points) or "I Know I cannot" (5 points). (Sallis et al., 1996) | Month 3 | |
Secondary | Exercise Confidence Survey in Controls | French version of the "Exercise Confidence Survey" for regular physical activity) according to Eeckhout et al. 2012. The ECS questionnaire measures perceived self-efficacy for regular physical activity. It has two dimensions in the Exercise Confidence Survey: "sticking to it" and "making time for exercise". The survey has 8 questions to be answered by "I Know I can" (1 point) "Maybe I can" (3 points) or "I Know I cannot" (5 points). (Sallis et al., 1996) | Month 6 | |
Secondary | Mediterranean diet adherence test in the Experimental Group | The MEDAS (Mediterranean diet Adherence Screener) score is a 14-point self-administered questionnaire used to assess adherence to a Mediterranean diet, based on consumption thresholds for 11 food groups (olive oil, vegetables, fruit, red meat, butter or cream, sweetened beverages, wine, legumes, fish, pastries and nuts), plus an additional question on preferential consumption of red or white meat. A score of 9 or over proves adherence to the Mediterranean diet. | Month 0 | |
Secondary | Mediterranean diet adherence test in the Experimental Group | The MEDAS (Mediterranean diet Adherence Screener) score is a 14-point self-administered questionnaire used to assess adherence to a Mediterranean diet, based on consumption thresholds for 11 food groups (olive oil, vegetables, fruit, red meat, butter or cream, sweetened beverages, wine, legumes, fish, pastries and nuts), plus an additional question on preferential consumption of red or white meat. A score of 9 or over proves adherence to the Mediterranean diet. | Month 3 | |
Secondary | Mediterranean diet adherence test in the Experimental Group | The MEDAS (Mediterranean diet Adherence Screener) score is a 14-point self-administered questionnaire used to assess adherence to a Mediterranean diet, based on consumption thresholds for 11 food groups (olive oil, vegetables, fruit, red meat, butter or cream, sweetened beverages, wine, legumes, fish, pastries and nuts), plus an additional question on preferential consumption of red or white meat. A score of 9 or over proves adherence to the Mediterranean diet. | Month 6 | |
Secondary | Mediterranean diet adherence test in Controls | The MEDAS (Mediterranean diet Adherence Screener) score is a 14-point self-administered questionnaire used to assess adherence to a Mediterranean diet, based on consumption thresholds for 11 food groups (olive oil, vegetables, fruit, red meat, butter or cream, sweetened beverages, wine, legumes, fish, pastries and nuts), plus an additional question on preferential consumption of red or white meat. A score of 9 or over proves adherence to the Mediterranean diet. | Month 0 | |
Secondary | Mediterranean diet adherence test in Controls | The MEDAS (Mediterranean diet Adherence Screener) score is a 14-point self-administered questionnaire used to assess adherence to a Mediterranean diet, based on consumption thresholds for 11 food groups (olive oil, vegetables, fruit, red meat, butter or cream, sweetened beverages, wine, legumes, fish, pastries and nuts), plus an additional question on preferential consumption of red or white meat. A score of 9 or over proves adherence to the Mediterranean diet. | Month 3 | |
Secondary | Mediterranean diet adherence test in Controls | The MEDAS (Mediterranean diet Adherence Screener) score is a 14-point self-administered questionnaire used to assess adherence to a Mediterranean diet, based on consumption thresholds for 11 food groups (olive oil, vegetables, fruit, red meat, butter or cream, sweetened beverages, wine, legumes, fish, pastries and nuts), plus an additional question on preferential consumption of red or white meat. A score of 9 or over proves adherence to the Mediterranean diet. | Month 6 | |
Secondary | Understanding barriers to motivation: Experimental group | The main barriers to physical activity cited by patients, and the responses provided by the healthcare professional - peer helper as part of therapeutic education sessions will be identified. Qualitative research | Month 0 | |
Secondary | Understanding barriers to motivation: Experimental group | The main barriers to physical activity cited by patients, and the responses provided by the healthcare professional - peer helper as part of therapeutic education sessions will be identified. Qualitative research | Month 3 | |
Secondary | Understanding barriers to motivation: Experimental group | The main barriers to physical activity cited by patients, and the responses provided by the healthcare professional - peer helper as part of therapeutic education sessions will be identified. Qualitative research | Month 6 | |
Secondary | Understanding barriers to motivation in Controls | The main barriers to physical activity cited by patients, and the responses provided by the healthcare professional - peer helper as part of therapeutic education sessions will be identified. Qualitative research | Month 0 | |
Secondary | Understanding barriers to motivation in Controls | The main barriers to physical activity cited by patients, and the responses provided by the healthcare professional - peer helper as part of therapeutic education sessions will be identified. Qualitative research | Month 3 | |
Secondary | Understanding barriers to motivation in Controls | The main barriers to physical activity cited by patients, and the responses provided by the healthcare professional - peer helper as part of therapeutic education sessions will be identified. Qualitative research | Month 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Completed |
NCT04507529 -
Peer-mentor Support for Older Vulnerable Myocardial Infarction Patients
|
N/A | |
Recruiting |
NCT06066970 -
Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery
|
||
Recruiting |
NCT03620266 -
Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI
|
N/A | |
Completed |
NCT04097912 -
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
|
||
Completed |
NCT04153006 -
Comparison of Fingerstick Versus Venous Sample for Troponin I.
|
||
Completed |
NCT03668587 -
Feasibility and Security of a Rapid Rule-out and rule-in Troponin Protocol in the Management of NSTEMI in an Emergency Departement
|
||
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Recruiting |
NCT05371470 -
Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation
|
N/A | |
Recruiting |
NCT04562272 -
Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP
|
N/A | |
Completed |
NCT04584645 -
A Digital Flu Intervention for People With Cardiovascular Conditions
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT06007950 -
Time-restricted Eating Study (TRES): Impacts on Anthropometric, Cardiometabolic and Cardiovascular Health
|
N/A | |
Withdrawn |
NCT05327855 -
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)
|
Phase 2 | |
Recruiting |
NCT02876952 -
High Intensity Aerobic Interval Training With Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients
|
N/A | |
Completed |
NCT02917213 -
Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
|
||
Completed |
NCT02711631 -
Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation
|
N/A | |
Completed |
NCT02552407 -
Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis
|
N/A | |
Completed |
NCT02382731 -
Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction
|
N/A |